WSNAF (Wesana Health Holdings) Debt-to-EBITDA : -1.89 (As of Sep. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WSNAF Wesana Health Holdings Inc WSNAF
12 GF Score
Price $0.00
View Full Analysis

What is Wesana Health Holdings Debt-to-EBITDA?

Wesana Health Holdings WSNAF 12 Debt-to-EBITDA is -1.89 as of Sep. 2024. GuruFocus rates WSNAF with a GF Score™ of 12/100.

Debt-to-EBITDA measures a company's ability to pay off its debt.

Wesana Health Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $0.25 Mil. Wesana Health Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $0.00 Mil. Wesana Health Holdings's annualized EBITDA for the quarter that ended in Sep. 2024 was $-0.13 Mil. Wesana Health Holdings's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 was -1.89.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Wesana Health Holdings's Debt-to-EBITDA or its related term are showing as below:

WSNAF's Debt-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 1.14
* Ranked among companies with meaningful Debt-to-EBITDA only.

Wesana Health Holdings  (OTCPK:WSNAF) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Wesana Health Holdings Debt-to-EBITDA Related Terms

Wesana Health Holdings Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Wesana Health Holdings's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Wesana Health Holdings Debt-to-EBITDA Chart

Wesana Health Holdings Annual Data
Trend Apr20 Apr21 Dec22 Dec23
Debt-to-EBITDA
0.00 0.00 -0.10 -0.12

Wesana Health Holdings Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.05 -0.50 -0.30 -0.32 -1.89

WSNAF vs BPTH, HEPA, SCPX: Debt-to-EBITDA Comparison

For the Biotechnology subindustry, Wesana Health Holdings's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Wesana Health Holdings Debt-to-EBITDA vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Wesana Health Holdings's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Wesana Health Holdings's Debt-to-EBITDA falls into.


WSNAF
12GF Score
Wesana Health Holdings Inc WSNAF
Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Wesana Health Holdings Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Wesana Health Holdings's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.25 + 0) / -2.02
=-0.12

Wesana Health Holdings's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.25 + 0) / -0.132
=-1.89

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2024) EBITDA data.

Frequently Asked Questions Learn more about Debt-to-EBITDA →
What does a Debt-to-EBITDA of -1.89 mean?
Wesana Health Holdings (WSNAF) has a Debt-to-EBITDA of -1.89 as of Sep. 2024. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Wesana Health Holdings.
Is Wesana Health Holdings' Debt-to-EBITDA too high?
Wesana Health Holdings' current Debt-to-EBITDA is -1.89. Overall, Wesana Health Holdings has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Wesana Health Holdings' Debt-to-EBITDA compare to BPTH and HEPA?
Wesana Health Holdings' Debt-to-EBITDA of -1.89 can be compared against companies in the Biotechnology industry. The industry median Debt-to-EBITDA is 1.14. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.14, based on 291 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Wesana Health Holdings. For the Biotechnology industry, the median Debt-to-EBITDA is 1.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Wesana Health Holdings's current Debt-to-EBITDA is -1.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wesana Health Holdings stock overvalued right now?
Wesana Health Holdings (WSNAF) has a current Debt-to-EBITDA of -1.89. The current Debt-to-EBITDA is -1.89. Wesana Health Holdings' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Wesana Health Holdings (WSNAF), the current Debt-to-EBITDA is -1.89 as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Wesana Health Holdings Business Description

Address 745 Thurlow Street, Suite 2400, Vancouver, BC, CAN, V6E 0C5
Wesana Health Holdings Inc is looking for new business opportunities.
12GF Score

Get the complete analysis for WSNAF

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price